News | April 27, 2008

Protein Identifies Those at High Risk for Type 2 Diabetes

April 28, 2008 - Researchers at the University of Warwick have found a that the protein E-selectin is a marker for endothelial dysfunction and sub-clinical systemic inflammation, which can help identify a far greater number of people at high risk for future development of type 2 diabetes.

In a study led by Saverio Stranges, M.D., associate professor of Cardiovascular Epidemiology at Warwick Medical School at the University of Warwick, the team looked at the protein E-selectin, whose presence is an indication of endothelial dysfunction, white blood cell count and levels of albumin, which are markers for sub-clinical systemic inflammation.

They found high levels of E-selectin and white blood cell count with low levels of serum albumin were clear predictors of high risk for type 2 diabetes. The researchers found that traditional risk factors such as obesity or family history helped identify 65 percent of all patients who were at high risk of developing type 2diabetes. But when the information from these three markers was added this increased from 65 percent to 73 percent, which means doctors could be able to spot a greater number of people at risk of type 2 diabetes at an early stage.

The research used data taken from the Western New York Health Study. This was a six-year longitudinal study of diabetes and cardiovascular risk factors among residents of Erie and Niagara Counties, New York.

Dr. Stranges said: "High levels of E-selectin and white blood cells with low levels of serum albumin can indicate endothelial dysfunction and sub-clinical systemic inflammation. These findings corroborate the notion that both these conditions play an important role in the development of the disease. Endothelial dysfunction is also regarded as a key event in the development and progression of atherosclerosis. Finding new markers for type 2 diabetes will help us gain a greater understanding of the condition and possibly open up new possibilities for the way we prevent and treat it."

For more information: http://www.ncbi.nlm.nih.gov/pubmed/18356828?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

Related Content

Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing | April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing | April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing | April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing | March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing | January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc.
Overlay Init